For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.

Contact Us Visit ClinicalTrials.gov


First-in human study in aviremic, immunocompetent people living with HIV on antiretroviral therapy (ART).


Long term follow-up study for EBT-101.

Requests for Expanded Access

This Policy for Requests for Expanded Access to Investigational Drugs describes the principles and procedures that Excision BioTherapeutics, Inc. will follow when considering requests by licensed physicians for use of Excision’s investigational drugs outside of clinical trials.

View Policy

Expanded Access Policy for EBT-101

Excision BioTherapeutics, Inc. is committed to designing well-structured clinical trials, overseen by experienced investigators, ensuring that the safety and efficacy are appropriately reviewed by regulatory authorities. After careful review of the considerations governing expanded access, we determined that our clinical trials are the most appropriate way to access our investigational products at present. For this reason, we do not currently offer an expanded access program (EAP). As a commitment to patients who could benefit from our investigational products, we will continue to re-evaluate this policy and provide ongoing updates on our website.

We encourage interested patients on stable antiretroviral therapy with latent HIV to search www.clinicaltrials.gov for the locations and contact information of our clinical trial sites conducting EBT-101 studies.   

If you are a health care provider who is interested in learning more about EBT-101 or a physician investigator with questions about participation in one of our clinical trials, please submit a request to clinicalscience@excisionbio.com. Excision will make every attempt to acknowledge questions as soon as possible, usually within five business days of receipt.

For further information on “expanded access” please refer to the FDA website: https://www.fda.gov/news-events/public-health-focus/expanded-access

For further information on HIV studies and HIV cure please refer to the NIH website:


If applicable, this website will be updated with hyperlinks to the relevant expanded access information on www.clinicaltrials.gov upon activation. As authorized by and in accordance with the 21st Century Cures Act, Excision reserves the right to revise this expanded access policy at any time. 

The safety and efficacy of the investigational use of this product have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.